Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
334.6 GBX | -0.42% | -1.76% | +3.40% |
May. 17 | Rotork begins buyback of up to GBP50 million in shares | AN |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Sales 2024 * | 752M 955M | Sales 2025 * | 793M 1.01B | Capitalization | 2.87B 3.64B |
---|---|---|---|---|---|
Net income 2024 * | 118M 150M | Net income 2025 * | 134M 170M | EV / Sales 2024 * | 3.63 x |
Net cash position 2024 * | 134M 170M | Net cash position 2025 * | 187M 237M | EV / Sales 2025 * | 3.38 x |
P/E ratio 2024 * |
24.4
x | P/E ratio 2025 * |
21.4
x | Employees | 3,342 |
Yield 2024 * |
2.28% | Yield 2025 * |
2.45% | Free-Float | 99.42% |
Latest transcript on Rotork plc
1 day | -0.42% | ||
1 week | -1.76% | ||
Current month | +3.46% | ||
1 month | +4.43% | ||
3 months | +4.17% | ||
6 months | +5.02% | ||
Current year | +3.40% |
Managers | Title | Age | Since |
---|---|---|---|
Kiet Huynh
CEO | Chief Executive Officer | 45 | 17-12-31 |
Ross Pascoe
CTO | Chief Tech/Sci/R&D Officer | - | 22-11-30 |
Paul Burke
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Janice Stipp
BRD | Director/Board Member | 64 | 19-12-31 |
Dorothy Thompson
CHM | Chairman | 63 | 22-11-30 |
Timothy Cobbold
BRD | Director/Board Member | 61 | 18-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 746 M€ | -.--% | - | |
0.02% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 334.6 | -0.42% | 1,890,014 |
24-05-16 | 336 | -0.53% | 634,152 |
24-05-15 | 337.8 | +0.30% | 902,701 |
24-05-14 | 336.8 | -0.71% | 718,287 |
24-05-13 | 339.2 | -0.41% | 1,104,181 |
Delayed Quote London S.E., May 17, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.40% | 3.64B | |
-5.65% | 5.93B | |
-9.08% | 367M | |
+13.18% | 191M | |
-28.84% | 186M | |
+0.63% | 151M | |
+1.45% | 53.09M |
- Stock Market
- Equities
- ROR Stock